Moleculin Biotech (MBRX)

Executive Summary

Moleculin Biotech is a Phase 3 clinical-stage pharmaceutical company focused on developing novel therapies for hard-to-treat cancers. Its lead asset, Annamycin, is a next-generation anthracycline designed to overcome multidrug resistance and eliminate cardiotoxicity, currently in a Phase 2/3 trial (NCT06788756) for relapsed/refractory acute myeloid leukemia (AML) in combination with cytarabine. The company also has a Phase 2 trial of STAT3 inhibitor WP1066 in glioblastoma (NCT05879250) and additional early-stage programs. With a market cap of ~$13M and a focused pipeline, Moleculin represents a high-risk, high-reward opportunity dependent on clinical data readouts. Upcoming catalysts include interim efficacy data from the AML trial and potential regulatory interactions.

Upcoming Catalysts (preview)

• Q4 2026Interim Data from Phase 2/3 AML Trial (Annamycin + Cytarabine)40% success
• Q2 2027Phase 2 Glioblastoma Trial (WP1066) Initial Efficacy Data30% success
• Q1 2027FDA Meeting or Regulatory Guidance for Annamycin in AML50% success